The endoplasmic reticulum (ER) is the cellular organelle responsible for protein folding and assembly, lipid and sterol biosynthesis, and calcium storage. The unfolded protein response (UPR) is an adaptive intracellular stress response to accumulation of unfolded or misfolded proteins in the ER. In this study, we show that the most conserved UPR sensor inositol-requiring enzyme 1 a (IRE1a), an ER transmembrane protein kinase/endoribonuclease, is required to maintain hepatic lipid homeostasis under ER stress conditions through repressing hepatic lipid accumulation and maintaining lipoprotein secretion. To elucidate physiological roles of IRE1a-mediated signalling in the liver, we generated hepatocyte-specific Ire1a-null mice by utilizing an albumin promotercontrolled Cre recombinase-mediated deletion. Deletion of Ire1a caused defective induction of genes encoding functions in ER-to-Golgi protein transport, oxidative protein folding, and ER-associated degradation (ERAD) of misfolded proteins, and led to selective induction of pro-apoptotic UPR trans-activators. We show that IRE1a is required to maintain the secretion efficiency of selective proteins. In the absence of ER stress, mice with hepatocyte-specific Ire1a deletion displayed modest hepatosteatosis that became profound after induction of ER stress. Further investigation revealed that IRE1a represses expression of key metabolic transcriptional regulators, including CCAAT/enhancer-binding protein (C/EBP) b, C/EBPd, peroxisome proliferator-activated receptor c (PPARc), and enzymes involved in triglyceride biosynthesis. IRE1a was also found to be required for efficient secretion of apolipoproteins upon disruption of ER homeostasis. Consistent with a role for IRE1a in preventing intracellular lipid accumulation, mice with hepatocytespecific deletion of Ire1a developed severe hepatic steatosis after treatment with an ER stress-inducing anti-cancer drug Bortezomib, upon expression of a misfolding-prone human blood clotting factor VIII, or after partial hepatectomy. The identification of IRE1a as a key regulator to prevent hepatic steatosis provides novel insights into ER stress mechanisms in fatty liver diseases associated with toxic liver injuries.
Introduction
Hepatosteatosis, characterized by excessive accumulation of triglycerides (TGs) in hepatocytes, is considered the key metabolic component of non-alcoholic fatty liver disease (NAFLD). Hepatic lipid accumulation is regulated by a complex network that involves lipogenesis, dietary fatty acid (FA) uptake, FA oxidation, and lipid transport/secretion (Musso et al, 2009) . Hepatic steatosis is the result of abnormal lipid metabolism caused by increased lipid delivery to the liver, increased de novo lipid biosynthesis, reduced lipid oxidation, and/or decreased lipid secretion (Postic and Girard, 2008; Musso et al, 2009) . Although significant progress has been made in understanding the metabolic pathways associated with hepatosteatosis, the molecular signal transduction network that triggers hepatic lipid dysregulation remains to be identified. Recent findings suggest that intracellular stress response pathways from the endoplasmic reticulum (ER) have important roles in regulating expression of lipogenic factors, secretion of apolipoproteins, lipid accumulation, and lipotoxicity (Scheuner et al, 2001; Feng et al, 2003; Wei et al, 2006; Zhang et al, 2006a; Lee et al, 2008; Ota et al, 2008; Oyadomari et al, 2008; Rutkowski et al, 2008) . This has raised an important notion that the ER stress response is an underlying mechanism governing the development of hepatosteatosis.
The ER is the site for folding of membrane and secreted proteins, synthesis of lipids and sterols, and storage of calcium in eukaryotic cells. A number of biological, physiological, or pathological stimuli can perturb protein folding in the ER, leading to accumulation of unfolded or misfolded proteins in the ER lumen-a condition referred to as 'ER stress' (Kaufman, 1999) . To deal with ER stress conditions, the ER has evolved a set of signal transduction pathways collectively termed the unfolded protein response (UPR) to alter transcriptional and translational programs in the stressed cell. In metazoans, there are three basic signal transducers of the UPR, inositol-requiring 1 (IRE1), PERK (double-strand RNA-activated protein kinase-like ER kinase), and ATF6 (activating transcription factor 6). The most conserved UPR transducer is IRE1, an ER transmembrane Ser/Thr protein kinase/endoribonuclease that was originally identified as the proximal sensor for the UPR in budding yeast (Nikawa and Yamashita, 1992; Cox et al, 1993; Mori et al, 1993) . The IRE1-mediated UPR signalling pathway is highly conserved in all eukaryotes. Two homologues of yeast ire1, Ire1a and Ire1b, were identified in both the murine and human genomes (Tirasophon et al, 1998; Wang et al, 1998) . In mammals, IRE1a is expressed in most cells and tissues, while IRE1b expression is primarily restricted to intestinal epithelial cells. The mRNA encoding X-box-binding protein 1 (XBP1), a basic-leucine zipper (b-ZIP)-containing transcription factor, was identified as an RNA substrate for the mammalian IRE1a endoribonuclease activity (Shen et al, 2001; Yoshida et al, 2001; Calfon et al, 2002) . Upon activation of the UPR, IRE1a initiates unconventional splicing of the Xbp1 mRNA to remove a 26-nucleotide intron and generate a switch in translational-reading frame. Spliced Xbp1 mRNA encodes a potent transcriptional activator that induces transcription of genes encoding functions that facilitate protein folding, secretion, and degradation in response to ER stress.
In addition to functions that are strictly involved in protein folding, trafficking, secretion, and degradation, the UPR is now recognized to have important physiological roles in metabolism, inflammation, as well as cell differentiation and survival (Ron and Walter, 2007; Todd et al, 2008; Zhang and Kaufman, 2008a) . IRE1a and its endoribonuclease target Xbp1 mRNA are required for the differentiation and function of specialized cell types, and have been proposed to contribute to the pathogenesis of metabolic disease (Reimold et al, 2001; Zhang et al, 2005; Ron and Walter, 2007) . Under conditions of ER stress, activated IRE1a can bind to tumour necrosis factor-receptor-associated factor 2 (TRAF2), leading to activation of c-JUN N-terminal kinase (JNK) through apoptosis signal-regulating kinase 1 (Urano et al, 2000; Nishitoh et al, 2002) . This might provide stressed cells with survival or death signals by activating JNK-mediated signalling pathways. Additionally, the cytosolic domain of IRE1a can also recruit the pro-apoptotic BCL-2-associated X protein and BCL-2 antagonist, augmenting both the kinase and endoribonuclease activities of IRE1a (Hetz et al, 2006) . In the liver, ER stress and UPR signalling can be triggered by metabolic factors, such as lipids, glucose, cytokines, homocysteine, and free FAs (Zhang and Kaufman, 2008a) . In this study, we generated hepatocyte-specific Ire1a-null mice. Using this animal model, we show that IRE1a is essential to maintain hepatic lipid homeostasis under conditions of ER stress in the liver. Deletion of the Ire1a gene results in profound hepatosteatosis and hypolipidemia in the mice upon ER stress. The identification of a key role of IRE1a in preventing ER stress-induced hepatosteatosis provides novel insights into potential avenues to limit hepatic lipid accumulation that contribute to metabolic syndrome.
Results

Hepatocyte-specific deletion of Ire1a is efficient
Homozygous Ire1a-null (Ire1a À/À ) murine embryos die by embryonic day 12.5, while the heterozygous Ire1a þ /À mice can survive as normal wild-type mice (Lee et al, 2002; Zhang et al, 2005) . The most significant phenotype of whole body Ire1a deletion, as well as Xbp1 deletion, was liver hypoplasis (Reimold et al, 2000; Zhang et al, 2005) . In order to study the tissue-specific and temporal roles of IRE1a in the mouse, we engineered mice with a loxP site-flanked Ire1a allele (Ire1a fe ) ( Figure 1A and B) (Hoess and Abremski, 1990 ). Mice with one or two floxed Ire1a alleles were viable, fertile, and apparently normal. Mice that harbour one floxed Ire1a allele and one Ire1a-null allele (Ire1a fe/À ) were bred with transgenic mice expressing Cre recombinase under the control of the albumin promoter (Postic and Magnuson, 2000) to obtain offspring with hepatocyte-specific Ire1a deletion (Ire1a Hepfe/À mice challenged with a sublethal injection of tunicamycin (TM), an inhibitor of N-linked glycosylation that causes accumulation of misfolded protein in the ER ( Figure 1C ). In comparison, significant levels of spliced Xbp1 mRNA were detected in the control Ire1a
Hepfe/ þ mice that harbour a wild-type Ire1a allele. We have not observed a difference in liver function between wild-type Ire1a þ / þ and our experimental control Ire1a Hepfe/ þ mice (data not shown). Mice with hepatocyte-specific Ire1a deletion (Ire1a Hepfe/À ) were viable and displayed no gross developmental or morphological defects ( Figure 1D ). Although livers from Ire1a
Hepfe/À mice appeared phenotypically normal in the absence of challenge, ultrastructural analysis revealed less rough ER content in the Ire1a-null (Ire1a Hepfe/À ) livers, compared with the littermate control (Ire1a Hepfe/ þ ) livers ( Figure 1E ), suggesting a possible ER defect in the absence of IRE1a.
To characterize the phenotype of hepatocyte-specific Ire1a deletion as well as the molecular targets of IRE1a in the liver, we performed Affymetrix GeneChip microarray analysis using total liver mRNA from Ire1a
Hepfe/À and control Ire1a
Hepfe/ þ mice injected with TM (2 mg/g body weight) induce acute ER stress in the liver (Zhang et al, 2006a) . Surprisingly, deletion of Ire1a caused only a slight alteration in gene expression in the absence of stress. Upon close analysis, we identified a subset of genes with reduced or increased expression that encoded functions associated with ER signal transduction and lipid metabolism ( Figure 2A ) (Table I) (Supplementary Figure S1A and B) . However, at 8 h after TM injection, the RNA expression profile in the Ire1a
Hepfe/À liver was significantly altered, compared with that characterized in the livers of control Ire1a
Hepfe/ þ mice ( Figure 2A ). The microarray results indicated that IRE1a is required for ER stress-mediated induction of genes involved in ER function, intracellular stress responses, lipid metabolism, cell differentiation, alternative mRNA splicing, and signal transduction ( Figure 2B ) (Table I) . Quantitative realtime PCR analyses confirmed that IRE1a is required for ER stress-induced expression of genes encoding functions in ER-to-Golgi protein transport (Sec22l1, Sec61a1, Sec24d, Tmed3), protein folding such as cis-trans proline isomerization and disulfide bond formation (Fkbp11, Pdi4, Ero1a, Ero1lb, P58 IPK ), and ER-associated degradation (ERAD) (Edem1, Hrd1, Erdj4, Erdj3) ( Figure 2C ). These results support the hypothesis that IRE1a is required to maintain ER function and remodel the secretory apparatus in response to protein misfolding in the ER.
Deletion of Ire1a causes UPR activation and defective adaptation to ER stress Next, we asked whether Ire1a deletion in hepatocytes alters ER homeostasis and activates the other UPR signalling pathways. To address this question, we first compared the expression of the ER chaperones GRP78/BiP and GRP94, two markers of the ER stress response, in the livers from hepatocyte-specific Ire1a-null (Ire1a Hepfe/À ) and control (Ire1a Hepfe/ þ ) mice after intraperitoneal injection of vehicle or TM. Expression of GRP78 and GRP94 in the Ire1a-deleted livers was modestly decreased compared with control livers from 8 to 72 h after TM treatment ( Figure 3A ). In comparison, the expression of ER stress-inducible pro-apoptotic transcription factors ATF4 (activating factor 4), CHOP (CCAAT/ enhancer-binding protein (C/EBP) homologous transcription factor), and ATF3 (activating factor 3) was significantly increased in the Ire1a-null livers compared with the control livers at 8-72 h after TM treatment ( Figure 3A ). Because ATF4, CHOP, and ATF3 were documented to be upregulated by the PERK/eIF2a subpathway of the UPR Scheuner et al, 2001; Wek et al, 2006) , we thought that the PERK UPR pathway may be activated by Ire1a deletion in hepatocytes. Although we failed to detect a significant increase in phosphorylation of PERK, phosphorylation of eIF2a was increased at the early time points in the Ire1a-null livers, compared with that in the control livers ( Figure 3B ). Furthermore, levels of the growth arrest and DNA damage-inducible protein 34 (GADD34), a PERK/eIF2a-regulated stress protein that has a feedback regulatory role by dephosphorylating eIF2a (Novoa et al, 2001) , were higher in 
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Figure 1 Hepatocyte-specific deletion of Ire1a. (A) Schematic illustration of the targeting vector and the Ire1a-null alleles. The targeting vector contained loxP-flanked exons 16 and 17 of the murine Ire1a gene as well as a loxP-flanked Neomycin (Neo) cassette. The engineered mice containing the targeted allele were backcrossed with ZP3-Cre transgenic mice in order to generate mice with the loxP-flanked Ire1a allele without the Neo cassette. This mouse strain was then crossed with heterozygous Ire1a-null mice (Lee et al, 2002; Zhang et al, 2005) to produce mice containing an Ire1a conditional allele (Ire1a fe ) and an Ire1a-null allele (Ire1a À ). (B) Genotyping of conditional Ire1a-null mice. Mice harbouring a conditional Ire1a allele in the presence of an Ire1a-null or wild-type allele were crossed with transgenic mice that express Cre recombinase under the control of the albumin promoter to generate hepatocyte-specific Ire1a-null mice (Ire1a Hepfe/À ) and control mice that harbour a functional Ire1a allele (Ire1a Hepfe/ þ ). Three pairs of PCR reactions were used for genotyping: one pair amplifies the targeted allele and the wild-type allele; a second pair amplifies the Neo cassette to identify the Ire1a-null allele (Lee et al, 2002; Zhang et al, 2005) ; and a third set amplifies the Cre transgene. (C) Semiquantitative reverse transcription (RT)-PCR of Xbp1 mRNA. Xbp1 mRNA splicing was not detected in livers of hepatocyte-specific Ire1a-null mice (Ire1a Hepfe/À ) at 8 h after intraperitoneal injection of TM (2 mg/g body weight). (D, E) Liver sections from hepatocyte-specific Ire1a-null (Ire1a Hepfe/À ) and control (Ire1a Hepfe/ þ ) mice in the absence of TM challenge stained with haematoxylin and eosin (magnification Â 200) (D) and transmission electron microscopy (magnification Â 19 000) (E).
the Ire1a-null livers at the early time points (0-24 h) after TM injection but comparable to that in the control livers at later time points (36-72 h) after TM injection ( Figure 3A) . It is possible that the induction of GADD34 causes dephosphorylation of eIF2a and PERK. These data suggest that Ire1a deletion in the liver leads to selective upregulation of ER stress-inducible pro-apoptotic factors ATF4, CHOP, and ATF3. This selective upregulation may reflect a defect in the ability of Ire1a-null livers to adapt to ER stress, as levels of cleaved caspase-3, the cell apoptosis executioner, and positive terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling (TUNEL) staining were increased in the Ire1a-null livers after TM treatment ( Figure  3A and D). Analysis of ATF6 cleavage indicated that it was increased in the Ire1a
Hepfe/À livers compared with the Ire1a
Hepfe/ þ livers, after TM challenge ( Figure 3C ), suggesting that Ire1a deletion also upregulates the ATF6 branch of the UPR in response to ER stress. Because IRE1a/XBP1 and ATF6 have redundant roles in activating expression of ER chaperones and protein-folding enzymes Lee et al, 2003b; Wu et al, 2007) , increased cleavage of ATF6 in Ire1a-null livers may compensate, at least partially, for the defect caused by Ire1a deletion in activating expression of UPR target genes.
To further evaluate the ability of Ire1a-null hepatocytes to adapt to prolonged ER stress, we treated immortalized Ire1a-null (Ire1a fe/À Cre) and control (Ire1a fe/fe ) hepatocytes with TM for up to 24 h in vitro. In response to TM, expression of ER stress-induced pro-apoptotic factor CHOP was significantly different between the Ire1a-null and control hepatocytes ( Figure 3E ). Although the Ire1a-null and control hepatocytes expressed similar levels of CHOP in the absence or presence of TM for up to 3 h, CHOP expression in the Ire1a-null hepatocytes was significantly greater than that in the control hepatocytes from 9 to 24 h after TM treatment ( Figure 3E ). CHOP expression in the control hepatocytes was induced from 3 to 9 h of TM treatment, but was subsequently attenuated, suggesting that the control hepatocytes adapted to ER stress at the later time points of TM treatment. In contrast, the Ire1a-null hepatocytes sustained high levels of CHOP expression up to 24 h after TM treatment ( Figure 3E ), suggesting the Ire1a-null cells are defective in their ability to adapt to prolonged ER stress. Hepfe/À and Ire1a Hepfe/ þ mice. Total liver mRNA was isolated at 8 h after injection with vehicle or TM (2 mg/g body weight) for real-time RT-PCR analysis. Expression values were normalized to b-actin mRNA levels. Fold changes of mRNA are shown in TM-treated mice compared with control mice. Each bar denotes the mean±s.e.m. (n ¼ 6 mice per group); *Po0.05, **Po0.01. P-values are shown for statistically significant differences. Edem1, ER degradation enhancing, mannosidase a-like 1; Sec22l1, SEC22 vesicle trafficking protein-like 1; Sec61a1, Sec61 a 1 subunit; Sec24d, SEC24-related gene family, member D; Tmed3, transmembrane emp24 domain containing 3; Pdi4, protein disulfide isomerase associated 4; Fkbp11, FK506-binding protein 11 of the peptidyl-prolyl cis-trans isomerase family; ERo1a, ER oxidoreductase-1 a, ERo1lb, ERO1-like b; Hrd1, or Syvn1, synovial apoptosis inhibitor 1; ERdj4, DnaJ (Hsp40) homologue, subfamily B, member 9; ERdj3, DnaJ (Hsp40) homologue, subfamily B, member 11; P58(IPK), or Dnajc3, DnaJ (Hsp40) homologue, subfamily C, member 3. The expression levels were indicated by normalized average expression values obtained through microarray. The table displays the genes whose expression was decreased or increased at least 1.5-fold in Ire1a-null liver, compared with the control, in response to TM treatment. Po0.05. The right column indicates ratios of KO versus CTL in TM-induced fold changes of gene expression. The genes whose expression was significantly different between knockout and control mice (without TM) was marked with an asterisk. CTL, control livers; KO, Ire1a-knockout livers.
Hepatocyte-specific Ire1a deletion increases hepatic lipid and reduces plasma lipid content upon ER stress
Having established a role for IRE1a in the chronic response to ER stress, we next investigated the physiological role of IRE1a in the liver. In hepatocytes, TG are synthesized in the ER and stored in the cytoplasm surrounded by a monolayer of phospholipid in distinct lipid droplet structures (Martin and Parton, 2006) . Although no morphological or developmental defects were observed in the hepatocyte-specific conditional Ire1a-null (Ire1a Hepfe/À ) mice, Oil-red O staining of liver tissue sections revealed a slight increase in lipid content in livers from the Ire1a
Hepfe/À mice ( Figure 4A ). Under normal physiological conditions, lipid droplets maintain energy balance at the cellular and organismal levels. As a response to acute liver injury induced by sublethal doses of TM, lipid deposition is increased in the hepatocytes of wild-type mice (Yang et al, 2007; Rutkowski et al, 2008) . To test the role of IRE1a in hepatic lipid accumulation in response to ER stress, we injected Ire1a
Hepfe/À and control Ire1a Hepfe/ þ mice with a dose of TM that can induce strong ER stress in the liver in vivo (Zhang et al, 2006a; Wu et al, 2007) . At 24 h after TM injection, the livers from control mice displayed modest macrovesicular steatosis characterized by engorgement of the hepatocytes with larger lipid droplets ( Figure 4B ). In contrast, in the livers of Ire1a
Hepfe/À mice, TM injection induced profound microvesicular steatosis characterized by Hepfe/À and Ire1a Hepfe/ þ mice at 3 months of age after intraperitoneal injection of TM (2 mg/g body weight) for 8, 24, 36, 48, and 72 h. Mice injected with the vehicle (150 mM dextrose) were included as the control time point 0. (A) Semiquantitative RT-PCR analysis of Xbp1 mRNA splicing and western blot analysis of GRP94, GRP78/BiP, ATF4, ATF3, CHOP, GADD34, and caspase-3. Levels of a-tubulin were included as internal controls. The values below the gels represent protein signal intensities that were quantified using NIH ImageJ software and normalized to a-tubulin. Cre) and control (Ire1a fe/fe ) hepatocytes challenged with TM (2 mg/ml) for indicated times. Ire1a-null and control hepatocytes cultured in the absence of TM (at 0 and 24 h) were included as controls. Levels of GAPDH protein were determined as internal controls. The values below the gels represent protein signal intensities after normalization to GAPDH. C, control hepatocytes; K, Ire1a-null hepatocytes. Hepfe/ þ mice was significantly resolved, as only small amounts of lipid droplets were detected in their livers ( Figure 4C ). In contrast, the Ire1a-null livers remained steatotic at 72 h after TM treatment, suggesting a role for IRE1a in preventing and recovering from ER stress-induced hepatic steatosis. Interestingly, at 72 h after TM treatment, Ire1a-null livers displayed macrovesicular steatosis instead of microvesicular steatosis that occurred at 24 h after TM treatment. This suggests that the formation of larger lipid droplets may be delayed in the Ire1a-null livers under conditions of ER stress. To further analyse the phenotype caused by Ire1a deletion at the subcellular level, ultrastructural analysis of liver sections was performed. In response to TM treatment, hepatocytes in the livers from Ire1a
Hepfe/À mice displayed significantly more lipid droplets surrounding the nucleus, compared with the livers from TM-injected control Ire1a
Hepfe/ þ mice ( Figure 4D ). Taken together, these observations indicate that IRE1a is required to minimize lipid accumulation in response to acute ER stress.
Analysis of plasma lipid profiles demonstrated that the levels of low-density lipoproteins (LDLs) and TG were reduced by 28-55% in Ire1a
Hepfe/À mice, compared with that in control Ire1a
Hepfe/ þ mice ( Figure 4E ). The reduction in plasma lipid contents became more profound in Ire1a
Hepfe/À mice at 8 h after TM injection compared with control mice ( Figure 4E ). Analysis of the major lipid classes in the liver demonstrated that hepatocyte-specific Ire1a deletion increased cellular TG levels modestly in the absence of TM, and more significantly at 8 h after TM injection ( Figure 4F ). At 24 h after TM injection, the liver TG content in Ire1a
Hepfe/À mice continued to increase where TG levels were approximately six times greater than those observed in the livers Hepfe/ þ mice at 24 h after TM injection (magnification: Â 3500). (E) Levels of plasma lipids in the Ire1a Hepfe/À and Ire1a Hepfe/ þ mice at 8 h after injection with TM or vehicle. Chol, total plasma cholesterol; TG, triglycerides; HDL, high-density lipoproteins; (V) LDL, low and very low-density lipoproteins. Each bar denotes the mean ± s.e.m. (n ¼ 6 mice per group); *Po0.05. P-values are shown for statistically significant differences. (F) Levels of liver cellular lipids in the Ire1a
Hepfe/À and Ire1a Hepfe/ þ mice at 8 h after injection with TM or vehicle. CE, cholesterol ester; TG, triglycerides; FA, fatty acids; Chol, total liver cholesterol. Each bar denotes the mean±s.e.m. (n ¼ 3 mice per group); *Po0.05. from control Ire1a Hepfe/ þ mice injected with TM (Supplementary Figure S2A ). In contrast to TG, the levels of other neutral lipids, including cholesterol esters (CE), FAs, and cholesterol, were not significantly different between the livers of Ire1a
Hepfe/À and Ire1a Hepfe/ þ mice, even after TM injection ( Figure 4F ). Additionally, the liver content of phospholipids, including phosphatidylethanolamine (PtdEtn), phosphatidylcholine (PtdCho), and sphingomyelin, were not significantly affected by Ire1a deletion (Supplementary Figure S2B and C). Consistent with this observation, expression levels of phoshocholine cytidylyltransferase a (CCTa), the rate-limiting enzyme in PtdCho biosynthesis, were comparable in the livers from Ire1a
Hepfe/À and Ire1a Hepfe/ þ mice (Supplementary Figure S2D ). These findings suggest that the increased liver TG accumulation observed upon Ire1a deletion in hepatocytes was not due to any alteration in phospholipid synthesis.
IRE1a represses expression of lipogenic transcriptional activators upon ER stress
Hepatic lipid accumulation may be caused by different metabolic perturbations: increased FA delivery, increased de novo lipogenesis, decreased FA oxidation, or inadequate TG secretion as VLDL (Musso et al, 2009) . To understand the molecular basis underlying the hepatic steatosis in Ire1a-null livers, we analysed expression of genes that regulate lipid biosynthesis, transport, storage, oxidation, as well as lipid droplet formation. Through quantitative gene expression analyses, we found that Ire1a deletion in hepatocytes increased expression of three classes of lipogenic regulators or enzymes that are essential for hepatic lipid deposition: (1) transcription factors of the C/EBP family, peroxisome proliferator-activated receptor g (PPARg), and their downstream targets; (2) adipose differentiation-related protein (ADRP) and ER-associated fat-inducing transcripts (FITs); and (3) key enzymes required for TG biosynthesis ( Figure 5 ).
Originally identified as the master regulator of adipogenesis, the nuclear receptor PPARg has also been implicated in hepatic steastosis Schadinger et al, 2005; Tontonoz and Spiegelman, 2008) . The PPARg gene encodes two isoforms, PPARg1 and PPARg2, that are differentially expressed depending on the cell type and stress conditions (Fajas et al, 1997; Vidal-Puig et al, 1997; Dubuquoy et al, 2002; Yamazaki et al, 2010) . Expression of the Pparg2 mRNA in the liver tissues of Ire1a-null and control mice was barely detectable, either under non-stressed conditions or after TM treatment (Supplementary Figure S3) . In comparison, the levels of Pparg1 mRNA were slightly increased in the livers from Ire1a
Hepfe/À mice in the absence of TM challenge, and this difference became statistically significant after TM injection ( Figure 5A ). Additionally, other PPAR isoforms, including PPARa and PPARd, were not significantly affected by hepatocyte-specific Ire1a deletion ( Figure 5A ). These results suggest that PPARg1 is the major PPAR isoform that contributes to TM-induced hepatic steatosis. C/EBPb and C/EBPd act upstream of PPARg by directly binding to the PPARg promoter to induce its transcription (Wu et al, 1995 (Wu et al, , 1996 Tontonoz and Spiegelman, 2008) . PPARg can induce C/EBPa expression, and C/EBPa can itself bind to the C/EBP site in the Pparg promoter, providing for a stable, self-reinforcing regulatory loop. Compared with livers from control Ire1a
Hepfe/ þ mice, the livers from Ire1a Hepfe/À mice displayed increased expression of the C/ebpb and C/ebpd mRNAs, and this increase became statistically significant after TM treatment ( Figure 5A ). However, expression levels of C/ebpa mRNA were modestly decreased in the Ire1a-null livers, compared with that in the control livers, after TM treatment for 8 h ( Figure 5A ). This is consistent with the previous demonstration that ER stress downregulates C/EBPa expression (Rutkowski et al, 2008; Sha et al, 2009) . Furthermore, expression levels of the mRNA encoding liver X receptor a (LXRa) and carbohydrate responsive element binding protein (ChREBP) were increased in livers from Ire1a Hepfe/À mice ( Figure 5A ), compared with that in the control livers from Ire1a
Hepfe/ þ mice. LXRa and ChREBP are involved in the PPARg-regulated cascade and have important roles in the induction of lipogenesis and hepatic steatosis (Tontonoz and Spiegelman, 2008; Musso et al, 2009) . In addition to the upregulation of C/EBPb, C/EBPd, and PPARg, hepatocyte-specific Ire1a deletion also increased expression of key factors required for hepatic lipid droplet formation, including ADRP and fat-inducing transcript 2 (FIT2) after TM injection, and other PPARg target lipogenic genes, including aP2, Fat/Cd36, and Fsp27, in the liver tissue in response to TM treatment (Jiang and Serrero, 1992; Brasaemle et al, 1997; Kadereit et al, 2008; Matsusue et al, 2008; Musso et al, 2009) (Figure 5B and D; Supplementary Figure S4 ). Moreover, we also examined expression of other lipogenic genes upon hepatocyte-specific Ire1a deletion. Expression of the mRNAs encoding key enzymes required for de novo hepatic TG biosynthesis, including stearyl coenzyme A (CoA) desaturase 1 (SCD1), diacylglycerol acetyltransferase 1 (DGAT1), DGAT2, and acetyl CoA carboxylase 1, was significantly increased in the Ire1a-null livers after TM treatment ( Figure 5B ), which is consistent with the increased hepatic lipid accumulation in the Ire1a-null livers after TM treatment. Although transcriptional induction of the genes encoding sterol regulatory element binding protein 1c (SREBP1c), FA synthase (FASN), PPARa, PPARd, PGC-1a, and PGC-1b was suppressed by TM treatment, there was no significant difference in the expression of these genes between Ire1a
Hepfe/À and Ire1a Hepfe/ þ mice, either in the presence or absence of TM injection (Figure 5B and D; Supplementary Figure S5) . The gene expression correlated with the lipogenic phenotype in TM-induced hepatic steatosis, as the protein levels of C/EBPb, C/EBPd, PPARg, and ADRP were also increased in the Ire1a
Hepfe/À liver, compared with the control, in response to TM challenge ( Figure 5A-D) . Interestingly, in response to TM treatment, levels of SREBP1c precursor, but not its cleaved and activated form, were decreased in both Ire1a-null and control livers, while the levels of cleaved/active SREBP1c were slightly increased in the Ire1a-null liver after TM treatment ( Figure 5D ). Apparently, under conditions of TM treatment, reduced expression of the Srebp1c mRNA reflected levels of the SREBP1c precursor, but not its mature/functional form (Supplementary Figure S5 ; Figure 5D ). The inconsistency between transcriptional induction of specific lipogenic genes and TM-induced lipogenesis phenotype was further evidenced by induction of the genes involved in FA oxidation or uptake. Expression of the genes involved in FA oxidation, including Acox1, Cpt1a, and Cyp4a10, and the genes involved in FA uptake/transport, including Fatp2, Fat/Cd36, Fabp1, and Fabp4 (aP2), was modestly increased in the Ire1a
Hepfe/À liver, compared Figure S4) . However, our measurement of radiolabelled acetate incorporation suggested no significant difference in FA oxidation or uptake between the Ire1a-null and control primary cultured hepatocytes (data not shown), suggesting that feedback regulation may be involved in the Hepfe/À and Ire1a Hepfe/ þ mice at 8 h after injection with TM (2 mg/g body weight) or vehicle. Semiquantitative RT-PCR analysis was performed to measure the levels of spliced and unspliced Xbp1 mRNAs as an indicator of IRE1a activity in the livers (C, bottom panel). In western blot analysis of C/EBPb, we detected the C/EBPb LAP (liver-enriched transcriptional activator protein) isoform of about 35 kDa in the mouse liver tissue samples (Calkhoven et al, 2000) . Because PPARg2 was not detected at the mRNA level in the liver tissue in the absence or presence of TM challenge (A, B) , the PPARg signals from the western blot analysis likely reflected PPARg1. The experiments were repeated at least three times with consistent results, and representative data are shown. The values below the gels represent protein signal intensities after normalization to that of a-tubulin.
induction of specific lipid-associated genes in TM-induced hepatic steatosis models.
Interpretation of studies from gene-deleted organisms is always compromised by adaptive responses that may occur. To test whether IRE1a is directly involved in regulating expression of C/EBP family transcription factors under conditions of acute ER stress, we overexpressed wild-type or mutant forms of IRE1a in Ire1a-null hepatocytes. Upon accumulation of unfolded protein in the ER, IRE1a is activated through trans-auto-phosphorylation at Ser/Thr residues to elicit its endoribonuclease (RNase) activity (Schroder and Kaufman, 2005) . Previously, we demonstrated that Lys to Ala mutations that destroy IRE1a kinase activity (K599A) or RNase activity (K907A) decrease Xbp1 mRNA splicing, as well as expression of downstream UPR target genes ( Figure 6A ) (Tirasophon et al, 1998; Zhang et al, 2005) . To understand how IRE1a regulates expression of the lipogenic trans-activators C/EBPb and C/EBPd, we expressed wild-type IRE1a, kinase mutant IRE1a (K599A), RNase mutant (K907A) IRE1a, or spliced XBP1 by adenovirus delivery to immortalized Ire1a-null hepatocytes. To verify adenovirus-mediated expression, we examined Xbp1 mRNA splicing in the hepatocytes infected with these adenoviruses. In response to TM treatment, spliced Xbp1 mRNA was not detected in the mock-infected Ire1a-null hepatocytes or the hepatocytes infected with adenoviruses that express K599A or K907A IRE1a mutant. In contrast, spliced Xbp1 mRNA was detected in control hepatocytes (Ire1a fe/fe ) that harbour two floxed Ire1a alleles and Ire1a-null hepatocytes (Ire1a fe/À Cre) infected with adenovirus that expresses wildtype IRE1a or spliced Xbp1 ( Figure 6B ). Analysis of expression of C/EBP family members demonstrated that Ire1a-null hepatocytes express higher levels of C/ebpb and C/ebpd mRNAs than the control hepatocytes ( Figure 6C and D) , consistent with the in vivo results ( Figure 5A ). Expression of the K599A or K907A IRE1a mutant in the Ire1a-null hepatocytes did not reduce C/ebpb mRNA expression and only slightly reduced C/ebpd mRNA expression in response to TM treatment ( Figure 6C and D) . In contrast, expression of wild-type IRE1a in the Ire1a-null hepatocytes reduced both C/ebpb and C/ebpd mRNA expression to the levels similar to those observed in the control hepatocytes ( Figure 6C and D) , suggesting a direct role for IRE1a in modulating expression of C/ebpb and C/ebpd mRNAs in hepatocytes. Moreover, overexpression of the product of IRE1a RNase, spliced XBP1, failed to decrease levels of C/ebpb and C/ebpd mRNAs in the Ire1a-null hepatocytes ( Figure 6C and D) . Taken together, these data suggest that IRE1a can decrease C/ebpb and C/ebpd mRNA levels in response to ER stress through mechanisms involving its kinase and RNase activities. However, overexpression of spliced Xbp1 mRNA, the target of IRE1a RNase activity, did not reduce C/ebpb and C/ebpd mRNA levels in the Ire1a-null hepatocytes ( Figure 6C and D) . This suggests that IRE1a may downregulate C/EBPb and C/EBPd expression through alternative mechanisms rather than splicing of Xbp1 mRNA under conditions of ER stress. Hepfe/À mice exhibit decreased plasma lipids in the absence or presence of ER stress compared with control mice ( Figure 4E and F), we asked whether IRE1a is required for efficient secretion of lipoproteins into the plasma. To evaluate the involvement of IRE1a in the secretion of apolipoproteins, we first examined levels of ApoB in the liver and plasma samples from Ire1a-null (Ire1a Hepfe/À ) and control (Ire1a Hepfe/ þ ) mice in the presence or absence of TM treatment. Under the nonstressed condition, disruption of IRE1a did not significantly affect the levels of two ApoB isoforms, ApoB100 and ApoB48, in murine liver and plasma samples ( Figure 7A and B) . At 24 h after TM injection, more hepatic ApoB was present while less plasma ApoB was detected in Ire1a-null mice, compared with that in the control mice ( Figure 7A and B) . This observation suggests that IRE1a may be required for secretion of ApoB-containing lipoproteins under conditions of ER stress. To confirm this hypothesis, we analysed secretion rates of ApoB in primary hepatocytes isolated from Ire1a-null and control mice by pulse-label and pulse-chase experiments. ApoB was immunoprecipitated from cell lysates and media samples and analysed by SDS-polyacrylamide gel electrophoresis followed by fluorography. The pulse-chase experiments indicated that the secretion rates of both ApoB100 and ApoB48 were comparable between Ire1a-null and control hepatocytes under the non-stressed condition ( Figure 7C and D) . However, after 6 h of TM treatment, the secretion rates of ApoB48 were decreased in the Ire1a-null hepatocytes, compared with that in the control hepatocytes ( Figure 7C and D) . This observation is consistent with more dramatic reduction of plasma ApoB in Ire1a-null mice than the control mice when they were challenged with TM ( Figure  7A and B). Moreover, in either Ire1a-null or control hepatocytes, we did not detect any significant levels of secreted ApoB100 in response to TM treatment, supporting the TMmediated suppression of ApoB100 secretion suggested by western blot analysis with the Ire1a-null and the control mice ( Figure 7A-D) . Together, our observations suggest that IRE1a is required for hepatocytes to efficiently secrete ApoBcontaining lipoproteins under conditions of ER stress.
IRE1a is required for efficient secretion of plasma lipids
IRE1a protects from non-TM stress-induced hepatic steatosis
To further evaluate the role of IRE1a in preventing stressinduced hepatic steatosis in the absence of TM, we induced ER stress in the livers of Ire1a-null and control mice by alternative mechanisms. First, we treated the mice with the clinically relevant ER stress-inducing agent Bortezomib (also known as Velcade or PS-341). Bortezomib is a highly selective and reversible proteasome inhibitor that was approved for treatment of multiple myeloma and is in more extensive clinical trials for other solid tumour malignancies (Richardson et al, 2003 (Richardson et al, , 2006 . Although the mechanisms involved in its anti-cancer activity are still under investigation, Bortezomib was recently shown to activate the UPR and ER stress-associated apoptosis by inhibiting the 26S proteasome and ERAD (Lee et al, 2003a; Fribley et al, 2004; Nawrocki et al, 2005; Fels et al, 2008) . To test whether Bortezomib can cause ER stress-associated hepatic steatosis and whether IRE1a has a protective role in Bortezomibinduced hepatic steatosis, we administered Bortezomib into Ire1a-null (Ire1a
Hepfe/À ) and control (Ire1a Hepfe/ þ ) mice through tail-vein injection. Injection of Bortezomib induced ER stress in the liver, as evidenced by increased expression of spliced Xbp1 and Chop mRNAs in the liver of mice injected with Bortezomib ( Figure 8A) . Particularly, the expression of Chop mRNA in livers of the Ire1a Hepfe/À mice was significantly greater than that of Ire1a
Hepfe/ þ mice after Bortezomib treatment. Spliced Xbp1 mRNA in the liver from Ire1a
Hepfe/À mice was hardly detected (Figure 8A ), reflecting the absence of IRE1a. At 36 h after injection of Bortezomib, hepatic lipid accumulation was observed in the livers of Ire1a
Hepfe/ þ mice ( Figure 8B ). However, hepatic lipid accumulation in the Ire1a
Hepfe/À mice was greater than that observed in the Ire1a
Hepfe/ þ mice. Direct measurement of liver TG demonstrated that Bortezomib treatment increased TG accumulation in the Ire1a
Hepfe/À mice, compared with the Ire1a
Hepfe/ þ mice ( Figure 8C ). The increase in TG accumulation correlated with increased expression of key lipogenic regulators, including C/EBPb, C/EBPd and PPARg, in the livers of the Ire1a
Hepfe/À mice after Bortezomib treatment ( Figure 8D ). Together, these observations suggest that IRE1a is required to attenuate hepatic steatosis in response to ER stress.
Hepatic lipid accumulation can cause lipotoxicity, represented by hepatocyte apoptosis, in the pathogenesis of fatty liver disease (Jou et al, 2008; Malhi and Gores, 2008) . Consistent with this notion, increased expression of ER stress-induced pro-apoptotic factor CHOP was observed in the livers of the Ire1a
Hepfe/À mice ( Figure 8A and D) . TUNEL staining demonstrated that the percentage of apoptotic cells in the livers of Bortezomib-treated Ire1a
Hepfe/À mice was increased approximately five times compared with that of the Ire1a
Hepfe/ þ mice (Supplementary Figure S6) , suggesting that IRE1a has an important role in preventing ER stressinduced hepatic steatosis and apoptosis.
In addition to Bortezomib treatment, we utilized two pathophysiologically relevant stress models, expression of a human blood clotting factor VIII (hFVIII) that is prone to misfolding and partial hepatectomy, to test the involvement of IRE1a in stress-induced hepatic steatosis. Hydrodynamic DNA tail-vein injection of hFVIII expression vectors was used to direct expression of a misfolding-prone hFVIII in hepatocytes (Malhotra et al, 2008) . In this study, the hFVIII is a B-domain-deleted variant of hFVIII that is secreted as a functional clotting factor. Analysis of this molecule is significant because it has previously been used in human haemophilia A gene therapy studies directing FVIII expression to the hepatocyte (Pierce et al, 2007) . However, these approaches have not produced physiologically significant levels of hFVIII to date. Because newly synthesized hFVIII misfolds in the ER, ) and control (Ire1a fe/ þ ) mice were labelled with [ 35 S]methionine/cysteine for 25 min and then chased for the indicated times. For TM-treated samples, the primary hepatocytes were treated with TM (10 mg/ml) for 6 h before and throughout the pulse-chase experiments. Radiolabelled ApoB-containing apolipoproteins were immunoprecipitated from the cell lysates and the media with a rabbit anti-ApoB polyclonal antibody, and resolved by 5% SDS-polyacrylamide gel electrophoresis with fluorography. The experiments were repeated at least three times with consistent results, and representative data are shown. (D) Quantification of secretion rates of ApoB48-or ApoB100-containing apolipoproteins from Ire1a-null (Ire1a fe/À ) or control (Ire1a fe/ þ ) primary hepatocytes to culture media in the absence or presence of TM treatment, as indicated in the panel (C). Secretion rates of ApoB ¼ secreted ApoB48(100)/cellular ApoB48(100). Levels of secreted ApoB48(100) were quantified based on the signals of ApoB48(100) present in the culture media, and levels of cellular ApoB48(100) were quantified based on the signals of ApoB48(100) present in the cellular lysates of the Ire1a-null or control primary hepatocytes, as shown in the panel (C). A full-colour version of this figure is available at The EMBO Journal Online. the UPR is activated in mice that express hFVIII (Malhotra et al, 2008) . Analysis of hFVIII secreted into the plasma demonstrated that Ire1a deletion reduces the secretion efficiency of hFVIII, with concomitant intracellular accumulation of hFVIII antigen in the liver (Figure 8E ), although the mRNA expression for hFVIII was similar ( Figure 8F ). The decrease in hFVIII was selective as there was no difference in plasma albumin ( Figure 7B ). In support of the role of IRE1a in preventing ER stress-induced hepatic steatosis, FVIII expression caused greater lipid accumulation in Ire1a-null mice, compared with the control mice ( Figure 8G ). Moreover, Ire1a-null mice produced less plasma TGs but more hepatic TGs than the control mice after expression of hFVIII ( Figure 8H ). Additionally, expression of key lipogenic genes, including Dgat2, Acc1, Scd1, Adrp, and ChREBP, was increased in the Ire1a-null mice upon expression of hFVIII ( Figure 8I) .
The second pathophysiologic model we used to test the role of IRE1a in hepatic lipid homeostasis was partial hepatectomy, the surgical removal of liver (Fausto et al, 2006) . In the clinic, partial hepatectomies are performed for liver transplantation or for surgical removal of carcinoma or ) and control (Ire1a Hepfe/ þ ) mice at 3 months of age through hydrodynamic tail-vein injection. Liver tissues and blood plasma samples were collected at 24 h after the injection. (E) Levels of the hFVIII antigen in liver cellular lysates or plasma of Ire1a-null and control mice after the injection of the hFVIII expression vector. Each bar denotes the mean level of hFVIII antigen in plasma (ng/ml) or in liver tissue (ng/mg liver protein) ± s.e.m. hepatoma tumours (Fausto, 2001) . After partial hepatectomy, the livers from Ire1a-null mice displayed profound steatosis, as reflected by accumulation of hepatic lipid droplets and increased hepatic TGs, compared with the control mice (Supplementary Figure S7A and B) . Taken together, these additional non-TM pathophysiologic stress models further confirmed that IRE1a has a critical role in preventing stressinduced hepatic steatosis.
Discussion
Analysis of mice with hepatocyte-specific Ire1a deletion demonstrated that IRE1a is essential to maintain hepatic lipid homeostasis, especially under conditions of ER stress (Supplementary Figure S8) . Our findings show that (1) IRE1a is required for the expression of genes that encode functions critical for oxidative protein folding, protein transport from the ER to the Golgi, and ERAD; (2) Ire1a deletion leads to selective activation of ER stress-induced pro-apoptotic transcription factors; (3) Ire1a deletion in hepatocytes causes severe hepatic steatosis and hypolipidemia after ER stress challenge; (4) IRE1a modulates lipogenesis by downregulating expression of C/EBPb, C/EBPd, PPARg, and key enzymes for TG biosynthesis under conditions of ER stress; (5) IRE1a is required for efficient secretion of ApoB-containing lipoproteins; and (6) IRE1a protects the liver from hepatosteatosis in response to Bortezomib treatment, expression of the misfolding-prone hFVIII, or partial hepatectomy. These findings indicate that the most evolutionarily conserved UPR transducer IRE1a is required to repress lipid accumulation in the liver, especially when protein-folding homeostasis is disrupted in the ER.
Our studies demonstrate that deletion of Ire1a significantly alters ER function. This was reflected by defective induction of ER chaperones and enzymes that are required for protein oxidative folding, ER-to-Golgi trafficking, and ERAD (Figure 2) . Importantly, Ire1a deletion led to selective upregulation of the UPR-regulated pro-apoptotic transcription factors ATF4, CHOP, and ATF3 in response to ER stress ( Figure 3A) . Upon ER stress, induction of ATF4, CHOP, and ATF3 is regulated by the PERK/eIF2a subpathway of the UPR (Scheuner et al, 2001; Harding et al, 2003; Wek et al, 2006) . Interestingly, the Ire1a-null livers expressed much higher levels of ATF4, CHOP, and ATF3, compared with the control livers, although there was no significant activation of the PERK/eIF2a pathway at the later time points of ER stress treatment ( Figure 3A-C) . It is possible that elevated GADD34 expression promotes dephosphorylation of eIF2a and PERK after the longer periods of ER stress. At the later time points after TM treatment, the levels of ATF4, CHOP, and ATF3 proteins were diminished in control liver tissue and isolated hepatocytes, while their levels remained high in the Ire1a-null liver tissues and hepatocytes from 8 to 72 h after TM treatment ( Figure 3A and E). Because ATF4, CHOP, and ATF3 are ER stress-induced pro-apoptotic factors, our data suggest that IRE1a is required for cells or tissues to adapt to ER stress. This was further confirmed by increased caspase-3 cleavage and positive TUNEL staining in the Ire1a-null livers after TM treatment ( Figure 3A and D).
Our findings suggest that IRE1a protects from hepatosteatosis upon acute ER stress conditions through at least two regulatory mechanisms (Supplementary Figure S8) : (1) IRE1a attenuates C/EBPb, C/EBPd, and PPARg transcriptional control and (2) IRE1a is required for efficient secretion of apolipoprotein. PPARg has two major isoforms, g1 and g2, that are generated from the same gene by alterative RNA splicing (Fajas et al, 1997; Vidal-Puig et al, 1997) . PPARg2 is highly expressed in adipose tissue and is upregulated in steatotic livers of ob/ob mice, while PPARg1 is found at low levels in many tissues, including fat and liver tissues (Tontonoz et al, 1994; Dubuquoy et al, 2002; Schadinger et al, 2005; Zhang et al, 2006b; Musso et al, 2009; Yamazaki et al, 2010) . It was proposed that both PPARg1 and PPARg2 contribute to formation of fatty liver, although PPARg2 is more effective in activating the transcription of adipogenic and lipogenic genes than PPARg1 Gavrilova et al, 2003; Matsusue et al, 2003; Zhang et al, 2004; Yamazaki et al, 2010) . C/EBPb and C/EBPd induce transcription of PPARg by directly binding to the PPARg promoter (Wu et al, 1995 (Wu et al, , 1996 Tontonoz and Spiegelman, 2008) . Our findings indicate that IRE1a is required to repress expression of C/EBPb, C/EBPd, and PPARg1, but not PPARg2, in hepatocytes in response to acute ER stress imposed by TM treatment. In the absence of IRE1a, ER stress significantly increased expression levels of C/EBPb, C/EBPd, and PPARg1 in the liver ( Figure 5 ). Interestingly, our data suggest that overexpression of wild-type IRE1a, but not spliced XBP1, reduced expression of C/ebpb and C/ebpd mRNAs in the Ire1a-null hepatocytes in response to ER stress ( Figure 6C and D). Therefore, it is possible that IRE1a prevents ER stressinduced hepatic steatosis through transcriptional suppression or degradation of the C/ebpb and C/ebpd mRNAs upon ER stress. A recent study showed that C/EBPb can induce expression of the Xbp1 mRNA and that spliced XBP1 directly induces expression of C/EBPa during adipogenesis (Sha et al, 2009) . Consistent with a role of spliced XBP1 in expression of C/EBPa, expression of the C/ebpa mRNA was decreased in the Ire1a-null livers in the presence or absence of TM treatment ( Figure 5A ). Based on these observations, it is also possible that the upregulation of C/EBPb and C/EBPd in the Ire1a-null liver results from the feedback regulation caused by decreased expression of C/EBP1a. If that is the case, there may exist a regulatory loop in which IRE1a modulates expression of C/EBP family transcription factors under conditions of ER stress. Future studies are required to explore the mechanism by which IRE1a regulates expression of the mRNAs encoding the C/EBP transcription factor family upon ER stress.
In the absence of TM challenge, Ire1a-null mice displayed mild hepatic steatosis and decreased plasma lipids ( Figure  4A , E, and F). Based on the microarray analysis, the expression of genes involved in the endomembrane protein secretion machinery, including Sec61a1, Sec24d, and Tmed3, was slightly decreased in the Ire1a-null liver under the nonstressed condition (Table I ). This may lead to accumulation of hepatic lipids intracellularly, a possible cause of mild hepatic steatosis in the Ire1a-null liver. Moreover, slight increase in expression of lipogenic genes encoding C/EBPb, C/EBPd, PPARg1, LXRa, ChREBP, ADRP, FIT1, FIT2, DGAT1, and DGAT2 was observed in the liver of Ire1a-null mice under the non-TM-treated condition ( Figure 5A and B), which may partially account for the mild steatosis in the Ire1a-null livers under the basal condition. Our results show that upregulation of hepatic C/EBPb, C/EBPd, and PPARg1 in the absence of IRE1a correlates with increased expression of the ChREBP, Lxra, Adrp, Fit2, Fsp27, aP2, and Fat/Cd36 genes, the targets of PPARg and/or C/EBPb in lipogenesis and lipid storage, in response to ER stress (Figures 5A and 8I) . Consistent with the upregulation of these lipogenic trans-activators, expression of the genes encoding key enzymes required for TG biosynthesis and/or lipid droplet formation, including DGAT1, DGAT2, and SCD1, was significantly increased in the Ire1a-null livers after TM treatment ( Figure 5B ). Interestingly, a recent study showed that XBP1 positively regulates expression of the Scd1, Dgat2, and Acc2 mRNAs in the livers of mice fed a high-fructose diet . However, the requirement of IRE1a-mediated Xbp1 mRNA splicing for TG synthesis was not characterized in the study with conditional Xbp1-null mice. Alternatively, it is possible that IRE1a has different roles in regulating de novo lipogenesis under conditions of acute ER stress versus chronic metabolic stress. This raises an interesting possibility that hepatocytes may utilize the same ER stress sensor to achieve different outcomes in lipogenesis depending on the type and/or degree of the stress.
Assembly and secretion of ApoB-containing lipoproteins from hepatocytes are crucial to maintain hepatic lipid homeostasis (Musso et al, 2009; Rutledge et al, 2010) . Previous studies implicated that ER stress and UPR components are critically involved in ApoB protein biosynthesis, stability, and secretion (Ota et al, 2008; Qiu et al, 2009; Rutledge et al, 2009) . Our study showed that IRE1a is required for efficient secretion of ApoB-containing lipoproteins from hepatocytes to peripheral tissues (Figure 7) . Secretion rates of ApoB species in the primary hepatocytes from the Ire1a-null and control mice were comparable under non-stressed conditions, although levels of ApoB48 in Ire1a-null primary hepatocytes were slightly higher than that in the control hepatocytes ( Figure 7C and D) . In response to TM treatment, the secretion rates of ApoB proteins were more greatly decreased in the Ire1a-null hepatocytes, compared with that in the control hepatocytes, which may partially account for the hepatic steatosis and hypolipidemia in the hepatocyte-specific Ire1a-null mice. Note that TM treatment suppressed the production of the ApoB100 species in both cultured primary hepatocytes and in mice in vivo. The mechanism by which TM suppresses production of ApoB100, but not ApoB48, requires further elucidated.
Hepatic lipid accumulation can be caused by an imbalance of any of the pathways involved in FA and TG synthesis, export, uptake, and/or oxidation. We suspect that the accumulation of liver TG in the hepatocyte-specific Ire1a-null mice might be due to metabolic alterations. For example, excess diacylglycerol can be converted to TG (Leonardi et al, 2009) . Overexpression of spliced form of XBP1 was previously associated with increased level and activity of CCT, a rate-limiting enzyme in the biosynthesis of PtdCho (Sriburi et al, 2004 (Sriburi et al, , 2007 . However, Ire1a deletion in hepatocytes did not significantly reduce production of phospholipids, including PtdCho and PtdEtn, in the presence or absence of ER stress (Supplementary Figure S2) . Therefore, accumulation of hepatic TGs in Ire1a-null livers is unlikely due to impaired phospholipid metabolism. Moreover, in addition to the increased lipogenesis and defective apolipoprotein secretion in the Ire1a-null livers that we have identified, the accumulation of TGs and lipid droplets in the absence of IRE1a may result from abnormal lipid droplet assembly that occurs in the ER (Cases et al, 1998 (Cases et al, , 2001 Wolins et al, 2006) . For future studies, it will be important to determine whether any ER-associated enzymes involved in lipid droplet formation are regulated by IRE1a.
Bortezomib is the only FDA-approved proteasome inhibitor that is used to treat patients with multiple myeloma (Richardson et al, 2003 (Richardson et al, , 2006 . Although Bortezomib was originally developed based on its ability to prevent activation of NFkB, recent studies suggest that Bortezomib causes ER stress, hepatosteatosis, and hepatoxicity (Lee et al, 2003a; Rosinol et al, 2005; Fels et al, 2008; Hernandez-Espinosa et al, 2008; Rutkowski et al, 2008) . Our studies show that hepatocyte-specific Ire1a-null mice develop severe hepatic steatosis and apoptosis after Bortezomib treatment. Intravenous injection of Bortezomib caused ER stress in the liver, and IRE1a is required to attenuate Bortezomib-induced hepatoteatosis and apoptosis (Figure 8) . Therefore, the regulation of hepatic lipid homeostasis by IRE1a may exist under general conditions of acute ER stress, not only TM treatment. In addition, two additional non-TM pathophysiologic stress models, in vivo expression of a misfolding-prone hFVIII and partial hepatectomy, also demonstrated that IRE1a is required to prevent ER stress-induced hepatosteatosis (Figure 8E -I; Supplementary Figure S7 ). Taken together, our findings provide novel insights into hepatic lipid homeostasis that requires the UPR transducer IRE1a. Therefore, interventions to modulate IRE1a-mediated signalling may provide a therapeutic avenue to treat diseases associated with hepatosteatosis and hyperlipidemia.
Materials and methods
Materials
Chemicals were purchased from Sigma unless indicated otherwise. Synthetic oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville, IA). Antibodies against phosphorylated eIF2a, phosphorylated PERK, and phosphorylated JNK proteins were purchased from Cell Signaling Technologies, Inc. (Danvers, MA). Antibodies against ATF4, CHOP, ATF3, GADD34, C/ EBPa, C/EBPb, C/EBPd, and PPARg were purchased from Santa Cruz Biotechnologies, Inc. (Santa Cruz, CA). Antibody against ATF6 was purchased from Imgenex Corp (San diego, CA). Antibodies against GRP78/BiP and GRP94 were purchased from Stressgen (Ann Arbor, MI). Antibody against a-tubulin was purchased from Sigma. Antibody against SREBP1c was purchased from Thermo Scientific (Rockford, IL). Bortezomib reagent of clinical quality was kindly provided by Dr Joanne Wang at the Wayne State University School of Medicine.
Generation of IRE1a conditional knockout mice
A targeting vector for conditional deletion that spans exons 16 and 17 of the Ire1a gene was constructed in pFlox vector ( Figure 1A) . The region for deletion was 0.65 kb sequence that spans exons 16-17 with flanking intron sequence of the Ire1a gene. After production of chimeric mice and F1 progeny from selected targeted clones, ZP3-Cre-recombinase expression in vivo was utilized to select progeny with deletion of neomycin (Neo) gene cassette flanked by loxP sites, but not the loxP-flanked Ire1a gene sequence. This yielded a strain of mice with a loxP-flanked Ire1a gene allele (Ire1a an Ire1a-null allele (Ire1a fe/À ) ( Figure 1A ). Three sets of PCR amplifications were used for genotyping of Ire1a conditional null mice: (1) for PCR amplification of the Ire1a floxed and wild-type alleles, we used primer sequences: 5 0 -CAGAGATGCTGAGTGAAGAC-3 0 , and 5 0 -ACAGTGGTTCCTGTGAAGGT-3 0 . The floxed allele generates a 241-bp band and the wild-type allele produces a 377-bp fragment; (2) for PCR amplification of Neo gene cassette to identify the Ire1a-null allele, we used primer sequences as previously described (Lee et al, 2002) ; (3) for PCR amplification of the Cre transgene we used primer sequences: 5 0 -GCGGTCTGGCAGTAAAAACTATC-3 0 , and 5 0 -GTGAAACAGCATTGCTGT CAC TT-3 0 .
GeneChip microarray and bioinformatics analysis IRE1a conditional null (Ire1a
Hepfe/ þ ) mice of 3 months old were injected intraperitoneally with TM (2 mg/g body weight) or vehicle (150 mM dextrose), and liver tissue was isolated at 8 h after the injection. Total RNA was purified from liver tissues and subjected to Affymetrix microarray analysis. For each microarray replicate, 10 mg RNA was fragmented and hybridized to Murine Genome 430.2 gene chips following Affymetrix instructions. The microarray data were analysed using several software packages. D-Chip (2008 Version) (http://www. dchip.org) was used to normalize the data set (Li and Wong, 2001) . The median intensity from all unnormalized array chips varies from 93 to 179 with P call between 52.5-58.5%. The original signals were scaled towards the median intensity array in the group at the probe intensity level. Normalization was performed using a normalization curve with invariant probe sets. GeneSpring GX (Silicon Genetics, Redwood City, CA) was used to identify differentially expressed genes and hierarchical clustering. ANOVA was used to analyse the difference. The P-value cutoff was 0.05. Since there are 45101 probes in the Affymetrix Mouse 430.2 chip, the Benjamini and Hochberg false discovery rate was used for multiple testing corrections. All the significant genes between two groups were filtered with expression level based on 1.5-fold changes. DAVID 2008 version software was used to functionally analyse the differentially expressed gene annotations and their related biological pathways (Dennis et al, 2003) .
Transmission electron microscopy
Liver tissues were fixed with 1.25% formaldehyde, 2.5% glutaraldehyde, 0.03% picric acid in 100 mM sodium cacodylate buffer. After washing with 100 mM sodium cacodylate buffer, tissues were treated for 1 h with 1% osmium tetroxide and 1.5% potassium ferrocyanide, and then 30 min with 0.5% uranyl acetate in 50 mM maleate buffer, pH 5.2. After dehydration in ethanol, tissues were treated for 1 h in propylenoxide and then embedded in Epon/ Araldite resin. Ultrathin sections were collected on EM grids and observed by using a JEOL 1200EX transmission electron microscope at an operating voltage of 60 kV.
Mouse plasma lipid profiling
Mice were fasted for 8 h prior to euthanization and collection of blood samples. Levels of plasma lipids in the mice were determined enzymatically using commercial kits (Roche Diagnostics Corporation). Approximately 120 ml of mouse blood plasma was collected and subjected to analyses using commercial kits for total cholesterol (Roche cat #: 3 313 018), HDL (Roche cat #: 3 034 569), and Triglyceride (Roche cat #: 3 034 658) (Allain et al, 1974; Stein,1994) . Levels of plasma LDL were calculated based on the formula: LDL ¼ total cholesterol-HDL-(TGs/5).
Measurement of liver cellular lipids
Lipids were extracted from B50 mg of liver using a modification of the Bligh and Dyer procedure as previously described (Leonardi et al, 2009 ). Mice were fasted for 8 h prior to euthanization and sample collection. The amount of each major lipid class was measured by flame-ionization thin layer chromatography. TGs, cholesterol, and CEs were separated using hexane:ether (90/10, v/v). Phospholipids were resolved using chloroform:methanol:acetic acid:water (50/25/8/2, v/v/v/v). The lipids were identified by co-migration with authentic standards and quantified by comparison with known amounts of standard lipids. Additionally, measurement of levels of liver cellular TGs was performed using a TG assay kit according to the manufacturer's instructions (BioAssay Systems, ETGA-200). Briefly, B100 mg of fresh liver was homogenized in 500 ml PBS and then centrifuged to remove the tissue debris. The supernatant, including the fatty debris on top, was transferred into a new tube, and then add another 500 ml of 10% Triton-X100 in PBS was added for TG measurement using the kit.
Generation of immortalized Ire1a-null hepatocytes and recombinant adenoviral infection
Primary murine hepatocytes were isolated from mice harbouring floxed homozygous Ire1a alleles using a standard protocol (Berry et al, 1991) , and were immortalized by SV40 T antigen. Immortalized hepatocytes were treated with adenovirus-Cre in order to delete the floxed Ire1a exons. Recombinant adenoviruses for the overexpression of flag-tagged IRE1a (wild type and its mutant forms K599A and K907A) (Qiu et al, 2010) were kindly provided by Dr Yong Liu (Institute for Nutritional Sciences, Shanghai, China) and amplified using the AdEasy System (Stratagene). Adenovirus expressing spliced XBP1 was kindly provided by Dr Umut Ozcan (Harvard University) (Park et al, 2010) . Recombinant adenovirus expressing GFP was kindly provided by Dr Jiande Lin (University of Michigan). The Ire1a-null and control hepatocytes at about 60% confluency were infected with adenoviruses expressing IRE1a wild-type, its mutant forms, or spliced XBP1 at an MOI of 100 for 48 h before they were treated with TM at the indicated concentrations.
ApoB western blot analysis with mouse liver and plasma samples and ApoB pulse-chase experiments with mouse primary hepatocytes Liver tissue and blood plasma samples were isolated from Ire1a-null (Ire1a Hepfe/À ) and control (Ire1a Hepfe/ þ ) mice in the absence or presence of TM treatment (2 mg/g body weight) for 8 h. To prepare the samples for ApoB western blot analysis, the liver tissue samples were diluted three times and the plasma samples were diluted five times before they were denatured. The denatured samples were resolved by 5% SDS-polyacrylamide gel electrophoresis, transferred onto 0.45 mm PVDF membranes, and followed by the incubation with a rabbit anti-ApoB polyclonal antibody (a kind gift from Dr Zhouji Chen, Washington University). For the pulse-chase experiments with mouse primary hepatocytes, livers from both Ire1a-null (Ire1a Hepfe/À ) and control (Ire1a Hepfe/ þ ) were first perfused by HBSS supplemented with 8 mM HEPES (pH 7.35) and 1 mM sodium pyruvate followed by collagenase digestion. Hepatocytes were pelleted by centrifugation at 50 g for 2 min, washed three times with DMEM media, and then seeded in the collagen-coated plates with Williams E media. Cells were attached in the plates for 48 h before the pulse-chase experiments. Hepatocytes were labelled with [ 35 S]methionine/cysteine (140 mCi/ml) for 25 min and chased at the indicated times. For TM-treated samples, the cells were treated with TM (10 mg/ml) for 6 h before and throughout the pulsechase experiments. Labelled ApoB apolipoprotein complexes were immunoprecipitated from the cell lysates and the media with the anti-ApoB antibody, resolved by 5% SDS-PAGE gel, and exposed to a phosphoimager screen.
Oil-red O staining
Frozen liver tissue sections were stained with Oil-red O for lipid content according to the standard protocol. Briefly, frozen liver tissue sections of 8 mm were air dried, and then fixed in formalin. The fixed sections were rinsed with 60% isopropanol before they were stained with freshly prepared Oil-red O solution for 15 min. After Oil-red O staining, liver sections were rinsed again with 60% isopropanol. Nuclei were lightly stained with alum haematoxylin 5.
TUNEL for apoptosis
To visualize the apoptotic events in the liver tissue sections of Ire1a-null and control mice, we used a fluorescent TUNEL staining kit (Clontech) to detect DNA fragmentation with the paraffin-embedded tissue section slides according to the manufacture's instruction (Zhang and Kaufman, 2008b) . The apoptotic cells exhibited green fluorescence using a standard fluorescein filter set (520 ± 20 nm). The cells were also stained with propidium iodide (PI), to identify all cells by strong red cytoplasmic fluorescence. The percentage of apoptotic cells was determined by calculating the number of TUNEL-positive cells divided by the number of PI-positive cells from five fields of each slide.
Hydrodynamic tail-vein injection and quantification of hFVIII antigen
We expressed a misfolding-prone hFVIII (B domain-deleted of human FVIII) that has a secretion defect like the wild-type hFVIII in murine liver using hydrodynamic tail-vein injection (Malhotra et al, 2008) . Plasmid DNA samples (100 mg) were diluted in 2.5 ml lactated Ringer buffer and infused over 10 s into the tail-vein as previously described (Miao et al, 2004) . Retro-orbital blood collection was performed at 24 h after injection for measurement of hFVIII activity and antigen in the plasma (Miao et al, 2004) . The hFVIII antigen was quantified by using an anti-human FVIII light-chain sandwich ELISA from Affinity Biologicals Inc. (Ancaster, Canada).
Statistics
Experimental results are shown as mean ± s.e.m. (for variation between animals or experiments). The mean values for biochemical data from the experimental groups were compared by a paired or unpaired, two-tailed Student's t-test. Statistical tests with Po0.05 were considered significant.
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
